What the experts are saying about Mirum Pharmaceuticals MIRM in recent reports within the last quarter:

Explore the 12-month price targets set by 12 analysts for Mirum Pharmaceuticals in the last 3 months. The average price target is $59.0, with a high estimate of $77.00 and a low estimate of $37.00.

Discover a summary of 12 analysts' ratings for Mirum Pharmaceuticals over the last 3 months. Increased bullish ratings indicate a positive sentiment, while increased bearish ratings signal a negative outlook.

A negative shift in sentiment is evident as analysts have decreased the average price target by 17.19%.

Decoding Analyst Ratings: A Detailed Look

Discover the analyses of financial experts and analysts, gaining insights into their recent evaluations for Mirum Pharmaceuticals. Our Ratings Table below provides a detailed overview of the actions taken by key analysts, their current ratings, and price targets. Grasping the perspectives of these experts on the company can unveil valuable insights into potential market trends and investor sentiment.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Mirum Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Mirum Pharmaceuticals compared to the broader market.
• Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Mirum Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Mirum Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Mirum Pharmaceuticals analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals: Delving into Financials

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Mirum Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 154.13%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Mirum Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -49.42%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Mirum Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -13.57%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Mirum Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -4.31% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Mirum Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 1.14. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

The Basics of Analyst Ratings

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.